It notes that iX Biopharma has started to commercialise its WaferiX subligual delivery of drugs as the company plans to expand capacity.
Moreover, the out-licensing of its sublingual ketamine wafer, Wafermine, for Phase 3 development will be a major catalyst for the company, says Phillip Securities.
“Specialty pharmaceutical and nutraceutical drugs will benefit from the planned six-fold increase in production capacity to meet the expected surge in demand,” Phillip Securities analyst Tay Wee Kuang writes in a note dated Oct 2.
As at 12.06 pm, iX Biopharma was up 1 cent or 4.3% at 24.5 cents with 10.7 million shares changed hands.
